Targeting Amyloid Plaques to Slow Cognitive Decline. Donanemab is a breakthrough monoclonal antibody therapy designed specifically for early symptomatic Alzheimer's disease.
Unlike medications that only manage symptoms, Donanemab aims to alter the course of the disease itself. It works by targeting and clearing out existing amyloid-beta plaques in the brain. By removing these toxic proteins, the goal is to slow down the progressive cognitive and functional decline associated with Alzheimer's.
| The TRAILBLAZER-ALZ Clinical Program | Primary Focus & Methodology |
|---|---|
| TRAILBLAZER-ALZ | The initial phase that demonstrated significant plaque clearance and a slowing of cognitive decline in early-stage patients. |
| TRAILBLAZER-ALZ 2 | A larger, Phase 3 trial focusing on definitive long-term outcomes, cognitive preservation, and safety monitoring (particularly regarding ARIA, or amyloid-related imaging abnormalities). |